# Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

Study · id `cardio:ct-nct04927299` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04927299](<https://clinicaltrials.gov/study/NCT04927299>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04927299

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.

## Technical summary

Registry record NCT04927299. Randomized; double masking; primary purpose treatment. Start 2022-06-30 (actual); primary completion 2023-08-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 163 participants (enrolled count; ClinicalTrials.gov record NCT04927299, source copy `cardio:ctgov-nct04927299-2025-03-13`, retrieved 2026-10-26)
- Started: 2022-06-30 (actual) (ClinicalTrials.gov record NCT04927299, source copy `cardio:ctgov-nct04927299-2025-03-13`, retrieved 2026-10-26)
- Primary completion: 2023-08-15 (actual) (ClinicalTrials.gov record NCT04927299, source copy `cardio:ctgov-nct04927299-2025-03-13`, retrieved 2026-10-26)
- Completion: 2023-09-11 (actual) (ClinicalTrials.gov record NCT04927299, source copy `cardio:ctgov-nct04927299-2025-03-13`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT04927299, source copy `cardio:ctgov-nct04927299-2025-03-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04927299-2025-03-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension
- Condition: Essential Arterial Hypertension
- Intervention (Drug): Losartan/Chlorthalidone in fixed dose
- Intervention (Drug): Losartan + hydrochlorothiazide in fixed dose
- Lead sponsor: Laboratorios Silanes S.A. de C.V.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Laboratorios Silanes S.A. de C.V. (`cardio:org-laboratorios-silanes-s-a-de-c-v`)

## Provenance

Content hash: 00302eb90f56f45e4f7648407aba12e6bd194620f246d5aa1687e0cc3e19791e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
